ADVERTISEMENT
Search

Newsroom

APhA Newsroom

Fast Facts

The American Pharmacists Association is the largest association of pharmacists in the United States advancing the entire pharmacy profession.

Membership: Pharmacists, pharmaceutical scientists, student pharmacists and pharmacy technicians

Governance: 501(c)(6) nonprofit organization, governed by a 15-member Board of Trustees. Its House of Delegates (411 members plus alternates) meets annually to determine overall policy.

Location: Washington, D.C.

Founded: October 6, 1852 in Philadelphia, PA

2020 Annual Report

Media Contact

Taneishia Bundy
APhA Media Relations
media@aphanet.org

Leadership

Press Releases

View all press releases

Published on Thursday, August 26, 2021

Patients on high doses of opioid analgesics risk overdose when tapering, study finds

A new study published in JAMA Network reveals that patients who take substantial amounts of opioid analgesics over the long term are at a greater risk of experiencing a mental health crisis or an overdose when they taper their dose. 

 

The researchers examined a database of more than 113,000 patients prescribed higher doses of opioid analgesics between 2008 and 2019—an average of about 50 morphine milligram equivalents per day—for at least 1 year. They used this information to identify patients who tapered their dose, which researchers defined as reducing it by at least 15% over a 60-day period. 

 

Researchers found that the group of patients who tapered their dose experienced a 68% increase in overdoses and twice the number of mental health crises compared with patients who stayed on their typical dose of medication. 

 

Those risks were more pronounced among patients whose original doses were higher and who reduced their doses more quickly. 

 

“Clinicians and patients must carefully weigh risks and benefits of both opioid continuation and tapering in decisions regarding ongoing opioid therapy,” the study authors write. “The risks associated with opioid tapering warrant further exploration to inform clinical guidelines regarding patient selection for tapering, optimal rates of dose reduction, and how best to monitor and support patients during periods of dose transition.

 

Although these findings raise questions about potential harms of tapering, they noted that interpretation is limited by the observational study design. 

Rate this article:
2.6
Comments (0)Number of views (50586)
Print
Please login or register to post comments.
Advertisement
Advertisement
Advertisement
Advertisement

ADVERTISEMENT